The Surprising Reason This Biotech Plummeted 69%
EyePoint Pharmaceuticals shares cratered following a late-stage trial setback for its flagship eye disease drug.
14 independently sourced, verified trend briefs about this subject.
Newsylist includes a story here only after at least four independent sources support it and its brief passes the verification check. The qualifying coverage spans 1 news category, from Jun 23, 2026 through Aug 17, 2026.
The cards below are ordered newest first. Each opens the underlying timeline, source list, coverage velocity and verification context; raw or extractive-only records are excluded.
EyePoint Pharmaceuticals shares cratered following a late-stage trial setback for its flagship eye disease drug.
Micron Technology shares are experiencing a sharp decline as a broader semiconductor sell-off intensifies, fueling debate over the company's valuation.
Meta stock has fallen for seven consecutive days as investors weigh concerns over high capital expenditures ahead of the upcoming Q2 earnings report.
U.S. stocks surge as a pause in U.S.-Iran tensions lifts markets, but a Fed decision this week keeps traders on edge.
Palantir faces conflicting market signals as a potential rating downgrade clashes with bullish growth estimates and rally predictions.
Investors are weighing a potential threat to the stock rally as oil prices reach $100 and bond yields remain near highs.
Healthcare stocks are drawing investor attention as some assets average 128% forward EPS growth amidst a broader market rotation.
Elon Musk's ventures face a massive valuation crisis as Tesla shares crash and SpaceX stock slides, fueling multibillion-dollar short-seller profits.
SpaceX shares face intense market pressure as the company hits new lows following its IPO, prompting warnings from Elon Musk directed at short sellers.
US chip stocks and big tech tumbled as China's Moonshot AI unveiled a powerful new model, triggering fears of a competitive 'DeepSeek moment'.
Netflix faces market volatility as growth deceleration and a shift in data reporting strategies spark investor concern.
Q32 Bio shares see significant gains following the release of positive 36-week trial data for its experimental alopecia areata drug, Bempikibart.
Global markets are experiencing volatility as a sharp stock decline at Samsung rattles investor confidence in the broader semiconductor and AI sectors.
A global tech sell-off is weighing on markets as the AI trade cools, impacting major players like Nvidia and Micron.